報價延遲最少15分鐘:2025/01/21 18:53 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.86 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.92/0.05
|
|
企業價值
151.58M
|
| 資產負債 |
|
每股賬面淨值
-0.67
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.43
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 18:53 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. |